X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ABBOTT INDIA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ABBOTT INDIA PFIZER/
ABBOTT INDIA
 
P/E (TTM) x 28.5 41.5 68.8% View Chart
P/BV x 4.5 10.4 43.8% View Chart
Dividend Yield % 0.7 0.6 110.2%  

Financials

 PFIZER   ABBOTT INDIA
EQUITY SHARE DATA
    PFIZER
Mar-16
ABBOTT INDIA
Mar-16
PFIZER/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs2,7246,015 45.3%   
Low Rs1,6113,707 43.5%   
Sales per share (Unadj.) Rs440.91,236.9 35.6%  
Earnings per share (Unadj.) Rs48.7122.2 39.9%  
Cash flow per share (Unadj.) Rs75.8129.0 58.7%  
Dividends per share (Unadj.) Rs15.0035.00 42.9%  
Dividend yield (eoy) %0.70.7 96.1%  
Book value per share (Unadj.) Rs462.9521.2 88.8%  
Shares outstanding (eoy) m45.7521.25 215.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.9 125.1%   
Avg P/E ratio x44.539.8 111.9%  
P/CF ratio (eoy) x28.637.7 75.9%  
Price / Book Value ratio x4.79.3 50.2%  
Dividend payout %30.828.6 107.5%   
Avg Mkt Cap Rs m99,163103,296 96.0%   
No. of employees `0002.93.0 97.7%   
Total wages/salary Rs m2,7583,370 81.8%   
Avg. sales/employee Rs Th6,981.78,891.8 78.5%   
Avg. wages/employee Rs Th954.51,140.0 83.7%   
Avg. net profit/employee Rs Th771.1878.3 87.8%   
INCOME DATA
Net Sales Rs m20,17026,284 76.7%  
Other income Rs m857504 170.0%   
Total revenues Rs m21,02826,789 78.5%   
Gross profit Rs m4,3103,665 117.6%  
Depreciation Rs m1,239144 857.8%   
Interest Rs m58 64.2%   
Profit before tax Rs m3,9234,017 97.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7941,421 126.3%   
Profit after tax Rs m2,2282,596 85.8%  
Gross profit margin %21.413.9 153.2%  
Effective tax rate %45.735.4 129.3%   
Net profit margin %11.09.9 111.8%  
BALANCE SHEET DATA
Current assets Rs m16,29914,446 112.8%   
Current liabilities Rs m7,5944,725 160.7%   
Net working cap to sales %43.237.0 116.7%  
Current ratio x2.13.1 70.2%  
Inventory Days Days6551 127.0%  
Debtors Days Days2620 131.7%  
Net fixed assets Rs m8,6221,113 774.7%   
Share capital Rs m458213 215.3%   
"Free" reserves Rs m20,72210,808 191.7%   
Net worth Rs m21,18011,076 191.2%   
Long term debt Rs m250-   
Total assets Rs m29,13716,241 179.4%  
Interest coverage x755.5497.0 152.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.6 42.8%   
Return on assets %7.716.0 47.8%  
Return on equity %10.523.4 44.9%  
Return on capital %19.036.3 52.3%  
Exports to sales %0.10.6 9.7%   
Imports to sales %17.512.6 138.3%   
Exports (fob) Rs m12162 7.4%   
Imports (cif) Rs m3,5263,322 106.1%   
Fx inflow Rs m52268 19.3%   
Fx outflow Rs m1403,927 3.6%   
Net fx Rs m-88-3,659 2.4%   
CASH FLOW
From Operations Rs m3,4362,514 136.7%  
From Investments Rs m-6,991-800 874.4%  
From Financial Activity Rs m-619-803 77.1%  
Net Cashflow Rs m-4,174912 -457.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 75.0 85.2%  
Indian inst/Mut Fund % 7.5 7.9 94.9%  
FIIs % 4.9 0.1 4,900.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.1 138.6%  
Shareholders   85,207 18,270 466.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 400 Points; HDFC Twins Up 3%(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading near all-time high levels.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jan 18, 2018 03:35 PM

TRACK PFIZER

PFIZER - AJANTA PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS